Literature DB >> 2745204

Results of radiotherapy in recurrent endometrial carcinoma: a retrospective analysis of 51 patients.

A Kuten1, P W Grigsby, C A Perez, B Fineberg, D M Garcia, J R Simpson.   

Abstract

A retrospective analysis was performed of 51 patients with locoregional recurrence of endometrial carcinoma, treated by radiotherapy between 1959 and 1986. There were 17 patients (33%) with isolated vaginal recurrence, 12 patients (24%) with vaginal recurrence with pelvic extension, 7 patients (14%) with pelvic recurrence only, and 15 patients (29%) with simultaneous locoregional and distant failure. Eighty percent of the recurrences occurred within 3.5 years from primary treatment; time to relapse was shorter in patients with advanced-stage, high-grade malignancy at original diagnosis. Locoregional control was achieved in 18 patients (35%). Complete tumor regression in the vagina, irrespective of extravaginal pelvic disease status or distant metastasis, occurred in 28 of 34 patients with vaginal involvement (82%). The 5- and 10-year overall actuarial survivals for all patients were 18 and 12.5%, respectively. The 5- and 10-year progression-free survivals of patients with isolated vaginal recurrences were 40% and 29%, respectively; the 5-year progression-free survival of patients with vaginal recurrence with pelvic extension was 20%. There were no survivors beyond 1.5 years among patients with pelvic recurrence (p = 0.02). All patients with simultaneous locoregional and distant failure were dead by 3.5 years. Stage at original diagnosis, time to relapse from primary treatment, histologic pattern, and grade of malignancy were prognosticators of survival. Five patients (10%) developed a total of ten radiation-related sequelae.

Entities:  

Mesh:

Year:  1989        PMID: 2745204     DOI: 10.1016/0360-3016(89)90366-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  [Isolated vaginal recurrences in endometrial carcinoma: treatment results using high-dose-rate intracavitary brachytherapy and external beam radiotherapy].

Authors:  R Pötter; T H Knocke
Journal:  Strahlenther Onkol       Date:  1998-09       Impact factor: 3.621

2.  Hematogenous metastases in patients with Stage I or II endometrial carcinoma.

Authors:  Paweł Blecharz; Krzysztof Urbański; Anna Mucha-Małecka; Krzysztof Małecki; Marian Reinfuss; Jerzy Jakubowicz; Piotr Skotnicki
Journal:  Strahlenther Onkol       Date:  2011-11-17       Impact factor: 3.621

Review 3.  Treatment for advanced and recurrent endometrial carcinoma: combined modalities.

Authors:  J Alejandro Rauh-Hain; Marcela G Del Carmen
Journal:  Oncologist       Date:  2010-07-21

4.  Adjuvant therapy in high-risk early endometrial carcinoma: a retrospective analysis of 46 cases.

Authors:  Jin Hwi Kim; Sung Jong Lee; Jeong Hoon Bae; Sung Ha Lee; Seog Nyeon Bae; Sung Eun Namkoong; Jong Sup Park
Journal:  J Gynecol Oncol       Date:  2008-12-29       Impact factor: 4.401

5.  A single-institution review of image-guided brachytherapy for vaginal malignancies using customized molded applicators and interstitial needles.

Authors:  Emily Flower; Salman Zanjani; Gemma Busuttil; Emma Sullivan; Wayne Smith; Kathy Tran; David Thwaites; Jennifer Chard; Viet Do
Journal:  J Contemp Brachytherapy       Date:  2021-12-30

6.  High-dose rate brachytherapy (HDRB) for primary or recurrent cancer in the vagina.

Authors:  Sushil Beriwal; Dwight E Heron; Robert Mogus; Robert P Edwards; Joseph L Kelley; Paniti Sukumvanich
Journal:  Radiat Oncol       Date:  2008-02-13       Impact factor: 3.481

7.  Use of a Flexible Inflatable Multi-Channel Applicator for Vaginal Brachytherapy in the Management of Gynecologic Cancer.

Authors:  Samuel M Shin; Tamara L Duckworth; Benjamin T Cooper; John P Curtin; Peter B Schiff; J Keith DeWyngaert; Stella C Lymberis
Journal:  Front Oncol       Date:  2015-09-14       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.